Clinical Trials with Melleril (TP21) in the Treatment of Schizophrenia

Abstract

The authors undertook to investigate the effects of two new phenothiazine derivatives on schizophrenic patients. Over a period of two years a series of clinical trials have been carried out on approximately 260 patients, some controlled, some uncontrolled. These drugs, known as Melleril (TP21) and KS75 are chemically related. Although Melleril was ultimately selected as the drug of choice we have, for statistical reasons, included some of the findings with KS75.